health π CanSinoBIO vaccine NDA accepted by China's NMPA
CanSino Biologics had its New Drug Application accepted by Chinaβs NMPA for its Td5cp Adolescent and Adult vaccine. This vaccine is designed as a booster shot for people aged six years and above in China. The NMPA granted Priority Review status in May 2026, while reported pertussis cases in China hit over 470,000 in 2024. This development is key against the backdrop of a global pertussis resurgence and China's push for life-course immunisation. If approved, it will complement their Tripecia vaccine for infants. π